CHMP recommends Hexyon/Hexacima vaccine (Sanofi Pasteur)
The CHMP has recommended market approval for the 6-in-1 pediatric vaccine Hexyon/Hexacima (DTaP-IPV-Hib-HepB vaccine), from Sanofi Pasteur. The new vaccine will be commercialized under the brand name Hexyon in Western European countries by Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur, and under the brand name Hexacima in Eastern European countries by Sanofi Pasteur. The new vaccine will be available in international markets under the trade name Hexaxim.
The vaccine protects infants against Diphtheria, Tetanus, Pertussis, Hepatitis B, Poliomyelitis and Infections caused by Haemophilus influenzae type b. Phase III clinical studies comparing Hexyon/Hexacima to licensed combination vaccines demonstrated that it is safe and induces a robust immune response against all six targeted diseases.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins